BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 27160747)

  • 1. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
    Pereira JM; Azevedo A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
    Rev Port Pneumol (2006); 2016; 22(6):308-314. PubMed ID: 27160747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
    Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
    Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.
    Bello S; Lasierra AB; Mincholé E; Fandos S; Ruiz MA; Vera E; de Pablo F; Ferrer M; Menendez R; Torres A
    Eur Respir J; 2012 May; 39(5):1144-55. PubMed ID: 22075489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
    Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
    Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
    Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM
    PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis.
    Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A
    J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia.
    Renaud B; Schuetz P; Claessens YE; Labarère J; Albrich W; Mueller B
    Chest; 2012 Dec; 142(6):1447-1454. PubMed ID: 22661450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission.
    Gonzalez Del Castillo J; Wilson DC; Clemente-Callejo C; Román F; Bardés-Robles I; Jiménez I; Orviz E; Dastis-Arias M; Espinosa B; Tornero-Romero F; Giol-Amich J; González V; Llopis-Roca F;
    Crit Care; 2019 Oct; 23(1):335. PubMed ID: 31665092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
    Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
    Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.
    Huang DT; Angus DC; Kellum JA; Pugh NA; Weissfeld LA; Struck J; Delude RL; Rosengart MR; Yealy DM
    Chest; 2009 Sep; 136(3):823-831. PubMed ID: 19363212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mr-Proadm Elevation Upon Icu Admission Predicts the Outcome of Septic Patients and is Correlated with Upcoming Fluid Overload.
    Charles PE; Péju E; Dantec A; Bruyère R; Meunier-Beillard N; Dargent A; Prin S; Wilson D; Quenot JP
    Shock; 2017 Oct; 48(4):418-426. PubMed ID: 28414691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
    Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
    Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia?
    Pereira JM; Teixeira-Pinto A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
    J Crit Care; 2013 Dec; 28(6):970-4. PubMed ID: 24216331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mid-regional pro-adrenomedullin predicts poor outcome in non-selected patients admitted to an intensive care unit.
    Bellia C; Agnello L; Lo Sasso B; Bivona G; Raineri MS; Giarratano A; Ciaccio M
    Clin Chem Lab Med; 2019 Mar; 57(4):549-555. PubMed ID: 30157027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study.
    Christ-Crain M; Morgenthaler NG; Struck J; Harbarth S; Bergmann A; Müller B
    Crit Care; 2005; 9(6):R816-24. PubMed ID: 16356231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.
    Bello S; Fandos S; Lasierra AB; Mincholé E; Panadero C; Simon AL; Gavin O; De Pablo F; Menendez R; Torres A
    Respir Med; 2015 Sep; 109(9):1193-206. PubMed ID: 26205553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Liu D; Xie L; Zhao H; Liu X; Cao J
    BMC Infect Dis; 2016 May; 16():232. PubMed ID: 27230573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of mid-regional pro-adrenomedullin, compared to other biomarkers (including lymphocyte subpopulations and immunoglobulins), as a prognostic biomarker in COVID-19 critically ill patients: New evidence from a 15-month observational prospective study.
    Montrucchio G; Sales G; Balzani E; Lombardo D; Giaccone A; Cantù G; D'Antonio G; Rumbolo F; Corcione S; Simonetti U; Bonetto C; Zanierato M; Fanelli V; Filippini C; Mengozzi G; Brazzi L
    Front Med (Lausanne); 2023; 10():1122367. PubMed ID: 37035317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: the experience of a single, Italian Center.
    Benedetti I; Spinelli D; Callegari T; Bonometti R; Molinaro E; Novara E; Cassinari M; Frino C; Guaschino R; Boverio R; Lauritano EC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1743-1751. PubMed ID: 33629344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidimensional Prognostic Index and pro-adrenomedullin plasma levels as mortality risk predictors in older patients hospitalized with community-acquired pneumonia: a prospective study.
    Pilotto A; Dini S; Veronese N; Daragjati J; Miolo M; Mion MM; Fontana A; Lo Storto M; Zaninotto M; Bragato G; Cella A; Carraro P; Addante F; Copetti M; Plebani M
    Panminerva Med; 2018 Sep; 60(3):80-85. PubMed ID: 29546738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.